Xtant Medical Collaborates with B2i Digital to Highlight Orthobiologics Innovation to Investors
Xtant Medical's partnership with B2i Digital aims to educate investors on its orthobiologics platform and market potential, showcasing its growth in the medical technology sector.
Xtant Medical Holdings has entered a partnership with B2i Digital to enhance investor understanding of its orthobiologics platform and market opportunities. This collaboration is set to provide centralized, investor-focused content, aiming to shed light on Xtant's comprehensive product line and its strategy for sustainable growth.
The company's vertically integrated model encompasses a wide range of regenerative medicine products, including bone-healing grafts and growth-factor biologics, supported by a strong R&D pipeline. With fiscal year 2024 revenue reaching $117.5 million, marking a 29% increase from the previous year, Xtant Medical demonstrates robust business fundamentals and a significant presence in the $2.5 billion U.S. orthobiologics market.
David Shapiro, CEO of B2i Digital, highlighted the timing of this partnership, noting Xtant's expansion and its appeal to investors interested in the medical technology sector. Sean Browne, CEO of Xtant Medical, expressed optimism about the partnership's role in communicating the company's growth story and value proposition to the investment community.